Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03690921
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 92
- Registration Number
- NCT03678428
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Conditions
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1579
- Registration Number
- NCT03675737
- Locations
- 🇨🇷
CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica
🇨🇷Policlinico San Bosco ( Site 3002), San Jose, Costa Rica
🇨🇷ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica
Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 215
- Registration Number
- NCT03668730
- Locations
- 🇨🇳
Hai Qiang Mai, Guangzhou, Guangdong, China
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 120
- Registration Number
- NCT03668418
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
- Conditions
- Stage II Ureter Cancer AJCC v8Stage II Urethral Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Urethral Urothelial CarcinomaStage II Renal Pelvis Cancer AJCC v8Stage III Bladder Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 2
- Registration Number
- NCT03617913
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 738
- Registration Number
- NCT03615326
- Locations
- 🇪🇸
Hospital Universitario Central de Asturias ( Site 1402), Oviedo, Asturias, Spain
🇺🇸Cancer Treatment Centers of America-Eastern Regional Medical Center ( Site 0025), Philadelphia, Pennsylvania, United States
🇺🇸University of Rochester ( Site 0041), Rochester, New York, United States
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 213
- Registration Number
- NCT03611556
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2023-12-18
- Target Recruit Count
- 270
- Registration Number
- NCT03607656
- Locations
- 🇨🇳
Longhua Hospital, Shanghai, Shanghai, China
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Leaf Vertical Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03607643
- Locations
- 🇺🇸
Southwest Cancer Center, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.